It would be nice for ACR MGN to break this out for us. The biggest problem i have is the lack to transparency / information provided to the market by ACR (Acrux) - this allows the shorts to run wild with the ACR stock price!
Axiron is a small product for Eli Lilly so doesn't really get the reporting coverage in terms of information. Surely ACR management should / can provide better detail about Axiron, its markets and other detail here!!!
What about Recuvyra - from memory ACR could receive $8m in milestones from this one as well... where's the detail!!!!
To be fair - ACR is yet to put anything out to the market about Q2 yet - but if they push out that same generic presentation again i will scream!!! its like every quarter - all they do is change the date on the presentation and push the same content with provide no more detail than the Eli Lilly spreadsheet data...
THIS IS NOT BEST PRACTICE INVESTOR RELATIONS HERE!!!
Q2 sales, page-4
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
